Stocktoria
Kymera Therapeutics, Inc. KYMR
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-08-21
Kymera Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $39.2M | $47.1M | $78.6M | $46.8M | $72.8M | $34.0M | $2.9M |
| R&D expense | $316.6M | $240.2M | $189.1M | $164.2M | $137.0M | $62.1M | $37.2M |
| Operating income | -$349.4M | -$261.6M | -$165.5M | -$161.3M | -$100.5M | -$46.3M | -$42.2M |
| Income tax | $0 | — | — | $0 | $0 | $0 | $0 |
| Net income | -$311.4M | -$223.9M | -$147.0M | -$154.8M | -$100.2M | -$45.6M | -$41.2M |
| EPS (diluted) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | — |
| Operating cash flow | -$232.9M | -$194.5M | -$102.8M | -$153.1M | -$128.9M | $88.1M | $17.9M |
| Free cash flow | -$234.3M | -$207.3M | -$137.3M | -$155.9M | -$130.5M | $79.0M | $17.4M |
| Cash & equivalents | $357.0M | $120.3M | $110.0M | $68.4M | $48.0M | $31.0M | $76.0M |
| Total assets | $1.7B | $978.0M | $575.8M | $603.1M | $605.9M | $487.2M | $116.7M |
| Total liabilities | $163.1M | $142.4M | $180.8M | $113.0M | $146.3M | $203.3M | $82.0M |
| Shareholders' equity | $1.6B | $835.6M | $395.0M | $490.2M | $459.6M | $283.9M | -$74.4M |
Growth · year-over-year · Revenue CAGR 54%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | -16.7% | -40.1% | +67.8% | -35.7% | +114.0% | +1060.0% | — |
| Free cash flow growth | — | — | — | — | -265.2% | +354.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.